IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Metabolic dysfunction-associated steatohepatitis, or MASH, is a disease at the intersection of metabolic and hepatic dysfunction — creating a complex clinical picture for people living with this ...

The button down shirt is fashion’s quiet overachiever: Crisp yet effortless, structured yet adaptable, it moves seamlessly between seasons and settings. In winter, it peeks out from beneath cozy knits ...

NEIGHBORS IN KANSAS AND MISSOURI. KANSAS CITY’S NEWS LEADER KMBC NINE NEWS. IT’S A DAVID VERSUS GOLIATH STORY THAT’S CONNECTING THE COMMUNITY TO A 108 YEAR OLD CANDY COMPANY. DAVID IS THE SAINT JOSEPH ...

For just the fifth time in history, one of the rarest and most coveted American whiskeys is hitting shelves. Michter’s Celebration Sour Mash Whiskey will go on sale in February 2026—in extraordinarily ...

The fifth release of the ultra-rare expression draws from seven barrels aged up to three decades—proving that in today’s top tier, composition matters more than age alone. When Michter’s Master of ...

Madrigal Pharmaceuticals (MASH) has reached an exclusive licensing agreement with China-based Suzhou Ribo Life Science to jointly develop treatments targeting a liver disease called metabolic ...

In response to rising food poverty, Comber-based Mash Direct has donated the equivalent of 265,000 portions of prepared vegetables over the past year to help tackle the crisis across Northern Ireland, ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. Just weeks after betting $50 million on a DGAT2i ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational ...

The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA interference medicines for the common liver condition. Madrigal surprised ...